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ABSTRACT
Background: Obesity is associated with inflammation but the role
of vitamin D in this process is not clear.
Objectives: We aimed to assess the associations between serum
25-hydroxyvitamin D [25(OH)D], BMI, and 16 inflammatory
biomarkers, and to assess the role of vitamin D as a potential mediator
in the association between higher BMI and inflammation.
Methods: Northern Finland Birth Cohort 1966 (NFBC1966) 31-y
data on 3586 individuals were analyzed to examine the observational
associations between BMI, 25(OH)D, and 16 inflammatory biomark-
ers. Multivariable regression analyses and 2-sample regression-based
Mendelian randomization (MR) mediation analysis were performed
to assess any role of vitamin D in mediating a causal effect of BMI
on inflammatory biomarkers [soluble intercellular adhesion molecule
1 (sICAM-1), high sensitivity C-reactive protein (hs-CRP), and α1-
acid glycoprotein (AGP)] for which observational associations were
detected. For MR, genome-wide association study summary results
ranging from 5163 to 806,834 individuals were used for biomarkers,
25(OH)D, and BMI. Findings were triangulated with a literature
review of vitamin D supplementation trials.
Results: In NFBC1966, mean BMI (kg/m2) was 24.8 (95% CI:
24.7, 25.0) and mean 25(OH)D was 50.3 nmol/L (95% CI:
49.8, 50.7 nmol/L). Inflammatory biomarkers correlated as 4
independent clusters: interleukins, adhesion molecules, acute-phase
proteins, and chemokines. BMI was positively associated with
9 inflammatory biomarkers and inversely with 25(OH)D (false
discovery rate < 0.05). 25(OH)D was inversely associated with
sICAM-1, hs-CRP, and AGP, which were positively associated with
BMI. The MR analyses showed causal association of BMI on
these 3 inflammatory biomarkers. There was no observational or
MR evidence that circulating 25(OH)D concentrations mediated the
association between BMI and these 3 inflammatory markers. Review
of randomized controlled trials (RCTs) supported our findings
showing no impact of vitamin D supplementation on inflammatory
biomarkers.
Conclusions: The findings from our observational study and causal
MR analyses, together with data from RCTs, do not support a
beneficial role of vitamin D supplementation on obesity-related
inflammation. Am J Clin Nutr 2020;111:1036–1047.
Keywords: vitamin D, BMI, obesity, Mendelian randomization,
mediation, inflammation, 25(OH)D
Introduction
Obesity is a global public health problem reaching epidemic
proportions (1), with estimated costs >$91 billion/y. Moreover,
obesity plays an important role in the development of chronic
diseases including the major cardiometabolic diseases (2, 3) and
certain forms of cancer. There is biological evidence supporting
that inflammatory biomarkers (Supplemental Table 1) could
mediate obesity-related pathological outcomes, and therefore
inflammation could be a modifiable target (2, 3).
The hormonal form of vitamin D, calcitriol, has immunomod-
ulatory properties acting via the vitamin D receptor (VDR) (4),
making it a potential mediator in the association between obesity
and inflammation (5). A review of 12 cross-sectional studies ex-
amining the association between vitamin D and inflammation has
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highlighted a possible link between vitamin D and inflammatory
biomarkers (Supplemental Table 2), albeit with some limitations
(6). This is substantiated by our own investigation on the in vitro
direct effects of calcitriol on inflammation-related pathways, the
NF-κB and mitogen-activated protein kinase (MAPK) pathways,
which have been demonstrated in multiple cell types including
isolated adipocytes (7, 8). Furthermore, vitamin D has been
reported to suppress the synthesis of IL-8, IL-6, and monocyte
chemoattractant protein 1 (MCP-1) (6, 7, 9). However, a recent
systematic review and meta-analysis that examined randomized
controlled trials (RCTs) looking at the effects of vitamin D
supplementation on 12 inflammatory biomarkers has reported no
beneficial effect of vitamin D supplementation for decreasing
inflammation (10).
In obesity, vitamin D insufficiency and inflammation often
co-occur (11–13), but it remains unclear whether low vitamin
D concentrations could exacerbate the inflammatory condition
associated with obesity. Evidence from Mendelian randomization
(MR) studies supports a causal relation between higher BMI
and lower vitamin D (11), as well as between higher BMI and
inflammatory biomarkers [e.g., high sensitivity C-reactive protein
(hs-CRP) (12) and α1-acid glycoprotein (AGP) (13)]. However,
it is not known whether the association between vitamin D
and inflammatory biomarkers is causal. Moreover, there is only
limited evidence for the efficacy of vitamin D supplementation in
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reducing the risk of obesity-related pathological outcomes (14).
RCTs with vitamin D supplementation in adults with overweight
or obesity have reported contradictory or inconsistent results. To
date, 13 completed (see Supplemental Table 3) and 55 ongoing
RCTs are testing the above-mentioned association.
In the current study we first used conventional observational
analyses to examine the cross-sectional associations between
1) BMI and 16 circulating inflammatory biomarkers, 2) serum
25(OH)D concentration and the same inflammatory biomarkers,
and 3) the role of vitamin D as a potential mediator in the
association of BMI and inflammatory biomarkers that were
observationally related to both BMI and vitamin D. We then
used MR mediation analyses to investigate whether vitamin D
is mediating any causal effect of raised BMI on inflammatory
biomarker concentrations that were observationally related to
both BMI and vitamin D. We finally reviewed the current
evidence on the impact of vitamin D supplementation on





We analyzed data from 3586 individuals using the Northern
Finland Birth Cohort 1966 (NFBC1966) 31-y follow-up (Sup-
plemental Figure 1). This population-based, longitudinal birth
cohort study comprised offspring of pregnant women, residing
in Northern Finland with expected delivery dates during 1966
(15). At 31 y of age (1997), the cohort members alive with a
known address were sent a postal questionnaire (75% response,
n = 8767). At the same time, those living in the original target
area (Northern Finland), or in the capital (Helsinki) area were
invited to a clinical examination, in which 71% (n = 6033)
participated (16). The attendees gave written informed consent
and the study was approved by the local ethical committee
of the University of Oulu. The procedures follow the 1964
Helsinki declaration and its later amendments or comparable
ethical standards.
Procedures.
Participants were invited to a clinical examination as described
previously (17). Height and weight were measured to an accuracy
of 0.1 cm and 0.1 kg, respectively, and converted to BMI (kg/m2).
LC-tandem MS was used to measure 25(OH)D2 and 25(OH)D3
concentrations, and total 25(OH)D [25(OH)D2 + 25(OH)D3]
concentration was computed. The detailed assay procedure has
previously been published, and the assay has been calibrated
using National Institute of Standards and Technology stan-
dard reference material (18). Plasma inflammatory biomarker
concentrations were analyzed by a multiplex array method
using human cytokine/chemokine magnetic bead panel and
nonmagnetic human CVD/cytokine panel (Cat# HCYTOMAG-
60K-12 and SPR349; Merck Millipore) (19) (detailed in the
Supplemental Methods). The 16 inflammatory biomarkers [IL-
17, IL-1α, IL-1β, IL-4, IL-6, IL-8, interleukin-1 receptor antago-
nist (IL-1RA) , interferon gamma-induced protein 10 (IP-10)/C-
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X-C motif chemokine 10 (CXCL10), MCP-1/CCL2, soluble
CD40-ligand (sCD40L/CD154), TNF-α, soluble vascular cell
adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion
molecule 1 (sICAM-1), active plasminogen activator inhibitor
(active PAI-1), hs-CRP, and AGP] examined in the study are
outlined in Supplemental Table 1. The inflammatory biomarker
measurements were performed according to the manufacturer’s
instructions (detailed in the Supplemental Methods). hs-CRP
(mg/L) concentration was measured by immunoenzymometric
assay (Medix Biochemica) (20). AGP (mmol/L) was measured
using high-throughput NMR spectroscopy (CV: 1.1%) (21).
Inclusion and exclusion criteria.
For the observational analyses we included those who attended
the 31-y follow-up assessment and who had data on 25(OH)D,
BMI, and inflammatory biomarkers (n = 3586). We excluded
participants with imprecise or missing information, and with
conditions susceptible to interfere via biological pathways
(kidney and liver diseases) with the measure of vitamin D
and/or the inflammatory markers. This included individuals with
nonfasting blood samples, those on lipid-lowering medications,
hs-CRP concentrations >10 mg/L (sign of acute infection), self-
reported fever during clinical assessment, or underweight (BMI
<18.5). In addition, we excluded women who were pregnant and
those reporting use of oral contraceptive pills (they interfere with
vitamin D metabolism and can also alter inflammatory process).
Covariates.
We included sex, season of blood sampling, smoking, alcohol
consumption, physical activity, and socioeconomic position as




Genome-wide association study (GWAS) summary statistics
for vitamin D were obtained from UK Biobank data in 337,199
individuals of European descent and downloaded from http://
www.nealelab.is/uk-biobank/(23, 24). GWAS summary statistics
for BMI were obtained from a GWAS meta-analysis of 806,834
individuals (25). The variant–inflammatory marker associations
were extracted from the published GWAS studies of CRP in
204,402 individuals (26), of AGP in 24,925 individuals (27), and
for sICAM-1 in 5163 individuals (28) (Supplementary file 2).
Ethical approval had been obtained in the original studies.
Statistical analyses
Observational associations of BMI and serum 25(OH)D with
inflammatory markers.
Descriptive statistics were generated for all explanatory
variables and outcome measures. The differences between
males and females were analyzed by chi-square test for
categorical variables, independent-sample Student t test for
normally distributed data, and Wilcoxon–Mann–Whitney U
test for nonparametric data. BMI, 25(OH)D, and inflammatory
biomarkers were all converted to standardized scores (z-scores).
Nonsupervised hierarchical clustering analysis was performed
for all the inflammatory biomarkers included in our study,
using a method adapted from Van den Ham et al. (29), and
the detailed methodology is explained in Schipper et al. (30).
Pearson correlation coefficients were used to assess the clustering
patterns and heatmaps were used to represent the correlations of
inflammatory biomarkers.
To assess the relation of BMI and serum 25(OH)D con-
centration with inflammatory biomarkers, we used adjusted
linear regression models. We first examined BMI–inflammatory
biomarker associations using 3 models; model 1 was unadjusted
(βc in Figure 1A), model 2 was adjusted for sex, and model 3
was adjusted for sex and potential covariates: smoking, alcohol,
physical activity, and socioeconomic position. We next tested the
association between BMI and serum 25(OH)D (βa in Figure 1A).
To examine 25(OH)D–inflammatory biomarker associations (βb
in Figure 1A), model 1 was adjusted for 25(OH)D batch, model
2 was further adjusted for sex and season of blood sampling,
model 3 was additionally adjusted for smoking, alcohol, physical
activity, and socioeconomic position, and model 4 included
model 3 covariates and additional adjustment for BMI (βc´ in
Figure 1A, Supplemental Table 4). Regression coefficients from
these associations can be interpreted as the change in 1 SD unit in
inflammatory biomarker per 1 SD increase in BMI or 25(OH)D.
P values were adjusted for multiple comparisons using the
Benjamini–Hochberg (1995) false discovery rate (FDR <0.05)
approach (31). Statistical analyses were performed using SAS
version 9.4 (SAS Institute Inc.) and R version 3.3.1 (R Project
for Statistical Computing).
Conventional mediation analysis of the association between
BMI and inflammation by 25(OH)D.
We tested 25(OH)D as a potential mediator in the observational
associations between BMI and the inflammatory markers using
the widely used method of Baron and Kenny (32) and the
Sobel test (33) for the inflammatory biomarkers (FDR < 0.05)
that were associated with both BMI and 25(OH)D from the
observational analyses above. Baron and Kenny proposed a 4-
step approach in which several regression analyses are conducted,
and significance of the coefficients is examined at each step. The
Supplemental Methods give further details for the methodology
of the conventional mediation analysis. As shown in Figure 1A,
mediation analysis assumes causality between all 3 components;
the exposure (BMI), outcome (inflammatory marker), and the
mediator [25(OH)D]. The statistical tests and P values were 2-
sided and statistical significance was set at P < 0.05.
MR analysis.
For those biomarkers that were associated with both BMI
and 25(OH)D in the conventional observational analysis, we
also performed MR to assess causality and mediation of any
effect of BMI on the inflammatory biomarkers through 25(OH)D
(Figure 1B and C). The Supplemental Methods give further
details of the principles relating to MR and MR mediation
analysis. Only genetic variants present for all GWAS summary
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FIGURE 1 Graphical representation of proposed mediation through 25-hydroxyvitamin D [25(OH)D] in the association of BMI with inflammatory
biomarkers: (A) mediation analysis; (B) Mendelian randomization (MR) analysis; and (C) MR mediation analysis. (A) βa represents the regression coefficients
for the association between BMI and 25(OH)D; βb represents the regression coefficients for the association between 25(OH)D and inflammatory biomarkers;
βc, represents the total effect between BMI and inflammatory biomarkers, without the adjustment for mediator; and βc´ represents the direct effect between
BMI and inflammatory biomarkers, taking into account adjustment for mediator. The regression models were adjusted for covariates (sex, socioeconomic
position, smoking, alcohol consumption, 25(OH)D batch, and physical activity). (B) A schematic representation of an MR analysis used in examining the
causal association between 25(OH)D and inflammatory biomarkers. (C) A schematic representation of the MR mediation analysis approach and the data
sources used (23–28). AGP, α1-acid glycoprotein; GWAS, genome-wide association study; sICAM-1, soluble intercellular adhesion molecule 1; SNP, single
nucleotide polymorphism.
data were considered (Supplemental file 2). The following
analyses were performed:
1) Total MR effects of BMI on 25(OH)D
2) Total MR effects of BMI on the inflammatory biomarkers
3) Total MR effects of 25(OH)D on the inflammatory
biomarkers
4) Any MR evidence of 25(OH)D mediating the effect of BMI
on the inflammatory biomarkers
For analyses considering total effects, instruments were
selected as single nucleotide polymorphisms (SNPs) that asso-
ciated with the exposure under consideration at genome-wide
significance (P < 5 × 10−8) and were in pairwise linkage
disequilibrium r2 < 0.001. To select instruments for mediation
analysis, all SNPs related to either BMI or 25(OH)D at genome-
wide significance were pooled and clumped to pairwise linkage
disequilibrium r2 < 0.001 based on the lowest P value for
association with any trait. All clumping was performed using the
TwoSampleMR package of R (34).
For analyses considering total effects, the random effects
inverse-variance weighted (IVW) meta-analysis MR method was
used for the main analysis, with the MR–Egger and weighted
median MR methods that make distinct assumptions about the
inclusion of pleiotropic variants used in sensitivity analyses (35).
As the MR–Egger and weighted median methods were only used
to support concordance with the main IVW findings, no statistical
significance threshold was applied for these. The intercept of the
MR–Egger regression offers a test for directional pleiotropy (36),
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with P < 0.05 used as the threshold for evidence of this. For
mediation analysis, summary data regression-based multivariable
MR was performed, as previously described (37). Briefly, genetic
instruments and associations for both BMI and 25(OH)D were
included in the same MR model to investigate their direct effects
on the inflammatory biomarkers after mutual adjustment. Any
attenuation in the direct MR effect of BMI after adjusting for
25(OH)D, as compared with those observed in the MR measuring
total effects of BMI, would support mediation through 25(OH)D.
All MR analyses were performed on R version 4.2.
RCTs of vitamin D supplementation and AGP.
A systematic review published recently (38) has examined
RCTs looking at the impact of vitamin D supplementation
on 12 inflammatory biomarkers including CRP and sICAM-
1, but not AGP, which was inversely associated with vitamin
D in our study. To validate our findings from observational
mediation and MR analyses, we performed a literature review
of the impact of vitamin D supplementation on the acute-phase
inflammatory biomarker AGP, using a similar protocol followed
in the previous investigation (38). Here we have included all
the search results identified using multiple databases including
PubMed/MEDLINE, Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, Web of
Science, and Google Scholar until January 2020 from a literature
search in relation to vitamin D and AGP (38).
RCTs of vitamin D supplementation in overweight and obese
individuals.
We further reviewed the completed and ongoing RCTs to
investigate the association between vitamin D supplementation
and circulating inflammatory biomarkers and metabolic health
outcomes of overweight and obese individuals. We performed
this investigation to compare our study findings from a general
adult population, which might provide additional information on
the role of vitamin D supplementation in improving inflammation
or health outcomes of overweight/obese individuals. To imple-
ment this, we examined the clinicaltrials.gov site “all studies”
with option “condition or disease” with the terms “obesity
and vitamin D” for reports published up to January 2020 in
English. We further searched for the “completed trials” and
further narrowed the search by choosing the option “completed
trials with results.”
Results
Study characteristics and the clustering pattern of
inflammatory biomarkers
The observational study included 3586 individuals (58% male)
(Table 1). Mean BMI was 24.8 (95% CI: 24.7, 25.0) and
mean serum 25(OH)D concentration was 50.3 nmol/L (95% CI:
49.8, 50.7 nmol/L). Except for hs-CRP and IL-17, all other
plasma cytokine concentrations were higher in men than in
women. There was no difference between complete (for all
individuals all data available) and incomplete data analysis (i.e.,
maximum sample size for each variable analyzed, data not
shown) (P > 0.05).
Figure 2 shows the correlation structure of the measured
inflammatory biomarkers. In our analysis and in line with
known biological function (31, 34), the inflammatory biomarkers
clustered into 4 groups: “cluster 1” all ILs and TNFα; “cluster 2”
adhesion molecules, that is, sICAM-1 and sVCAM-1; “cluster
3” acute-phase proteins, that is, active PAI-1, CRP, and AGP;
and “cluster 4” chemokines/CD154, that is, sCD40L/CD154,
CXCL10/IP-10, and CCL2/MCP-1.
The observational associations of BMI and serum 25(OH)D
with inflammatory markers
Figure 3 shows results from the multivariable regression
analysis of BMI and serum 25(OH)D with 16 inflammatory
biomarkers. In the fully adjusted model (model 3, FDR corrected,
βc in Figure 1A), BMI was positively associated with IL-6
and IL-1RA in cluster 1; sICAM-1 in cluster 2; active PAI-
1, hs-CRP, and AGP in cluster 3; and with sCD40L/CD154,
IP-10, and CCL2/MCP-1 in cluster 4. In contrast, BMI was
inversely associated with sVCAM-1 (β = −0.03; 95% CI: −0.07,
−0.002) in cluster 2. BMI was inversely associated with serum
25(OH)D concentration (βa = −0.05; P = 0.0005; Table 2). For
serum 25(OH)D (model 3, FDR corrected, βb in Figure 1A),
we observed inverse associations between 25(OH)D and IL-8
(β = −0.07; 95% CI: −0.11, −0.04), sICAM-1 (β = −0.05;
95% CI: −0.08, −0.008), hs-CRP (β = −0.04; 95% CI: −0.08,
−0.004), and AGP (β = −0.09; 95% CI: −0.13, −0.06).
Further adjustment of the association between 25(OH)D and
these inflammatory biomarkers for BMI (Supplemental Table 4)
showed no substantial change. We did not observe any interaction
between 25(OH)D and BMI, fulfilling the criteria for mediation
analyses.
Conventional mediation analysis of the association between
BMI and inflammation by 25(OH)D
Observational mediation analysis results for the 3 inflam-
matory biomarkers sICAM-1, AGP, and hs-CRP are shown in
Table 2. These 3 inflammatory biomarkers fulfilled the criteria
for examining causal relations using mediation analyses as
shown in Figure 1A; that is, the presence of an association
between all 3 components: the exposure (BMI), outcome
(inflammatory marker), and the mediator [25(OH)D]. In the
mediation analyses, when 25(OH)D was added into the model,
the association of BMI with AGP [βc´ = 0.26 (95% CI:
0.23, 0.29)] and sICAM-1 [βc´ = 0.12 (95% CI: 0.09, 0.15)]
decreased slightly, albeit with nil results (Sobel P value = 0.08).
In addition, the change in association of BMI with hs-CRP
was negligible when adjusted for 25(OH)D (Sobel P value =
0.41).
MR analysis
The MR analyses supported the causal effects of BMI on
the 3 inflammatory biomarkers (CRP, AGP, and sICAM-1) and
vitamin D (Table 3). There was no MR evidence of a causal
effect of vitamin D on concentrations of any of the 3 considered
inflammatory biomarkers (Table 4). The results of the MR–Egger
and weighted median sensitivity analyses were consistent with
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TABLE 1 Descriptive statistics in the Northern Finland Birth Cohort 1966 study1
Total population Males Females P value2




Season of blood sampling,3 % (n)
High vitamin D months 64.8 (2323) 65.1 (1350) 64.3 (973) 0.62
Low vitamin D months 35.2 (1263) 34.9 (723) 35.7 (540)
Socioeconomic position, % (n)
I + II (professional) 24.5 (877) 27.5 (571) 20.2 (306) <0.0001
III (skilled worker) 28.7 (1029) 18.1 (375) 43.2 (654)
IV (unskilled worker) 27.1 (974) 35.9 (745) 15.2 (229)
V (farmer) 3.8 (136) 4.7 (97) 2.6 (39)
VI (other)4 15.9 (570) 13.8 (285) 18.8 (285)
Smoking, % (n)
Nonsmoker 43.8 (1571) 40.2 (833) 48.8 (738) <0.0001
Smoker 56.2 (2015) 59.8 (1240) 51.2 (775)
Physical activity,5 MET h/wk (95% CI) 14.96 (14.5, 15.4) 14.95 (14.3, 15.6) 14.97 (14.3, 15.6) 0.84
Alcohol intake, g/d (95% CI) 10.0 (9.4, 10.5) 13.7 (12.8, 14.6) 4.8 (4.4, 5.2) <0.0001
BMI, kg/m2 (95% CI) 24.8 (24.7, 25.0) 25.2 (25.0, 25.3) 24.4 (24.2, 24.6) <0.0001
Total serum 25(OH)D, nmol/L (95% CI) 50.3 (49.8, 50.7) 51.3 (50.6, 51.9) 48.9 (48.2, 49.6) 0.014
Inflammatory biomarkers (95% CI)
IL-17, pg/mL 56.2 (49.4, 63.0) 56.1 (50.2, 62.0) 56.3 (42.3, 70.2) 0.166
IL-1α, pg/mL 73.5 (63.4, 83.7) 89.0 (73.4, 104.7) 52.3 (41.6, 63.1) <0.0001
IL-1β, pg/mL 6.7 (5.1, 8.2) 7.8 (5.1, 10.5) 5.1 (4.2, 5.9) 0.0001
IL-6, pg/mL 19.0 (14.7, 23.2) 21.0 (17.1, 24.8) 16.2 (7.6, 24.8) <0.0001
TNF-α, pg/mL 9.5 (8.4, 10.6) 10.8 (9.0, 12.6) 7.8 (7.0, 8.6) <0.0001
IL-1RA, pg/mL 67.9 (52.5, 83.2) 78.1 (55.3, 100.9) 53.8 (35.2, 72.3) <0.0001
IL-4, pg/mL 30.4 (25.8, 35.0) 35.7 (28.4, 43.0) 23.1 (18.7, 27.4) <0.0001
IL-8, pg/mL 38.8 (33.7, 44.0) 39.9 (36.7, 43.1) 37.3 (25.9, 48.7) <0.0001
IP-10, pg/mL 434.7 (422.4, 447.0) 448.7 (432.4, 465.0) 415.5 (396.9, 434.1) <0.0001
MCP-1, pg/mL 319.6 (315.5, 323.8) 349.4 (343.8, 355.1) 278.9 (273.4, 284.3) <0.0001
sCD40L, pg/mL 545.5 (525.0, 565.9) 588.9 (560.8, 616.9) 486.0 (456.7, 515.3) <0.0001
sICAM, ng/mL 147.2 (145.3, 149.1) 156.6 (154.0, 159.3) 134.2 (131.5, 136.9) <0.0001
sVCAM, ng/mL 1692.3 (1679.5, 1705.1) 1766.8 (1750.0, 1783.7) 1590.3 (1571.8, 1608.7) <0.0001
Active PAI-1, ng/mL 22.2 (21.2, 23.1) 26.2 (24.8, 27.5) 16.7 (15.7, 17.7) <0.0001
hs-CRP, mg/L 1.16 (1.11, 1.21) 1.15 (1.09, 1.22) 1.18 (1.10, 1.26) 0.097
α1-Acid glycoprotein, mmol/L 1.36 (1.35, 1.37) 1.39 (1.38, 1.40) 1.32 (1.31, 1.33) <0.0001
1Data are presented as percentages (n) or means (95% CI) as appropriate. Active PAI-1, active plasminogen activator inhibitor 1; hs-CRP, high
sensitivity C-reactive protein; IP-10, interferon gamma-induced protein 10; IL-1RA, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant
protein 1; sCD40L, soluble CD40 ligand; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; 25(OH)D,
25-hydroxyvitamin D.
2P value for heterogeneity between males and females is analyzed by chi-square test for categorical variables, Student t test for normally distributed
variables, and Wilcoxon–Mann–Whitney U test for nonnormally distributed variables.
3Proportions of samples taken during high vitamin D months [summer (June 1 to August 30), autumn (September 1 to October 31)] and low vitamin D
months [winter (November 1 to March 31) and spring (April 1 to May 31)].
4Includes students, pensioners, long-term unemployed, or not defined.
5MET is metabolic equivalent of task of physical activity.
those from the main IVW method. The MR–Egger intercept did
not provide evidence for the presence of directional pleiotropy in
any analysis.
In performing multivariable MR, there was no significant
attenuation in the effect of genetically predicted BMI on these 3
inflammatory biomarkers after adjusting for genetically predicted
vitamin D. There was no evidence of an effect of genetically
predicted vitamin D on the biomarkers after adjusting for
genetically predicted BMI (Table 5). These findings therefore
do not provide evidence to support any role of vitamin D in
mediating the effect of BMI on the 3 inflammatory biomarkers.
RCTs of vitamin D supplementation and AGP
Only 2 studies (39, 40) were identified where the impact of
vitamin D supplementation on AGP had been assessed. Summary
characteristics of the studies are presented in Supplemental
Table 5. The included studies were published between 2015 and
January 2020 from 2 different countries. One study reported
a decrease in AGP concentrations compared with baseline
in elderly women (39), whereas the other study reported no
difference between the control and placebo group in pregnant
women with vitamin D supplementation (40) (Supplemental
Table 5).
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FIGURE 2 Correlation heat maps for inflammatory biomarkers using Pearson correlation analysis. Red and white colors represent a positive and negative
correlation between the 2 inflammatory biomarker concentrations that meet at that cell, respectively. The darker and more saturated the color, the greater the
magnitude of the correlation.
RCTs of vitamin D supplementation in overweight and
obese individuals
From searches in the clinicaltrials.gov site we identified 13
completed and 55 ongoing RCTS that examine the association
between vitamin D supplementation and circulating inflamma-
tory biomarkers and metabolic health outcomes of overweight
and obese individuals. In 13 completed RCTs the dose of
vitamin D supplementation ranged from 400 IU/d to 150,000
IU/3 mo, duration of the trials was from 4 wk to 3 mo, and 1
study had vitamin D plus calcium supplementation. Four RCTs
reported a small increase in circulating 25(OH)D concentrations
in the overweight and obese individuals. However, subsequent
improvement in the inflammatory status or health outcomes
of overweight and obese individuals have not been reported
(Supplemental Table 3).
Discussion
In the present study, we integrated conventional observa-
tional and MR approaches, including mediation analyses, to
examine the role of 25(OH)D in the associations of BMI
with circulating inflammatory biomarkers in the adult general
population. We replicated the known positive associations of
BMI with inflammatory biomarkers, and the inverse association
of BMI and vitamin D. In addition, we have also shown that
in observational analyses 25(OH)D, reflecting the nutritional
vitamin D status, is inversely associated with 3 inflammatory
biomarkers (sICAM-1, CRP, and AGP) related to higher BMI.
This led us to examine the hypothesis that 25(OH)D was a
potential mediator in the association between BMI and these
inflammatory markers because all 3 factors [BMI, 25(OH)D,
and inflammatory markers] were observationally associated with
each other in the expected directions. However, we did not
find any evidence of such mediation when using conventional
observational or MR approaches.
The 16 inflammatory biomarkers analyzed in the present
study (Supplemental Table 1) correlated with each other forming
4 molecular clusters: ILs, adhesion molecules, acute-phase
proteins, and chemokines. The clustering pattern of inflammatory
biomarkers observed was in line with their biological response
or organization during an inflammatory stimulus (41, 42). The
inflammatory clusters we delineated were independent of each
other and reported for the first time in our study to the best
of our knowledge. The observed association between BMI and
the inflammatory clusters might link higher BMI to a chronic
state of inflammation (41, 42), which could be involved in the
development of obesity-related pathological consequences. In
addition, the results suggest that ≥4 different molecular and/or
organ-specific pathways are present that link inflammation and
cardiometabolic health outcomes.
Serum 25(OH)D concentration was inversely associated with
4 inflammatory biomarkers, IL-8, sICAM-1, CRP, and AGP, in
3 independent clusters (ILs, adhesion molecules, acute-phase
proteins). The observed results were in line with an earlier
experimental investigation, which reported downregulation of IL-
8 secretion by calcitriol through interference with NF-κB and
MAPK signaling pathways (43–45). The negative association be-
tween 25(OH)D and sICAM-1 could indicate the role of calcitriol
produced locally in endothelium, which results in downregulation
of sICAM-1 expression as reported in a few, but not all, studies
(38, 46, 47). Similarly, the association between 25(OH)D and
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FIGURE 3 Multivariable regression analysis on the association of BMI and 25-hydroxyvitamin D [25(OH)D] (exposure) with 16 inflammatory biomarkers
(outcome). The results are expressed as β coefficients change in inflammatory biomarkers (95% CI) per unit increase in BMI/25(OH)D. For BMI: model 1—
unadjusted; model 2—adjusted for sex; model 3—adjusted for sex and covariates (smoking, physical activity, alcohol intake, socioeconomic position). For
25(OH)D: model 1—adjusted for vitamin D batch; model 2—adjusted for sex and season of blood sampling; model 3—model 2 + adjusted for covariates
(smoking, physical activity, alcohol intake, socioeconomic position). ActivePAI-1, active plasminogen activator inhibitor 1; hs-CRP, high sensitivity C-reactive
protein; IP-10, IFNγ -induced protein 10; MCP-1, monocyte chemoattractant protein 1; sCD40L, soluble CD40 ligand; sICAM-1, soluble intercellular adhesion
molecule 1; sVCAM-1, soluble vascular cell adhesion molecule 1.
CRP remains controversial (38, 48). Furthermore, AGP in the
circulation may arise during stressful conditions and 25(OH)D
might play an inhibitory role in the regulation of AGP synthesis
through VDR (49). These results support the anti-inflammatory
function of calcitriol. In addition, the present study also
demonstrated an independent inverse association of 25(OH)D
with 3 inflammatory biomarkers even after adjusting for BMI
(Supplemental Table 4). When compared with all the previous
epidemiological investigations (Supplemental Table 2), our study
has considered adjustment for potential covariates when reporting
the associations of serum 25(OH)D with inflammatory biomark-
ers. In addition, serum 25(OH)D was inversely associated
with BMI, which is in accordance with previous investigations
(13, 50, 51).
In our observational analyses, BMI was positively associated
with hs-CRP, AGP, and sICAM-1, and serum 25(OH)D was
negatively associated with these inflammatory biomarkers. The
observational associations of BMI and 25(OH)D with inflam-
matory biomarkers were in the expected directions, supporting
a relation of higher BMI on higher inflammatory biomarkers
via lowering of serum 25(OH)D concentration. However, ob-
servational mediation analysis, MR, and MR mediation analysis
showed no evidence of a causal association between serum
25(OH)D concentration and the 3 inflammatory biomarkers
(hs-CRP, sICAM-1, and AGP). The findings suggest that the
association between 25(OH)D and inflammatory biomarkers
from cross-sectional studies could be in part due to residual
confounding (8).
In addition, a systematic review and meta-analysis that
examined the RCTs to evaluate the impact of vitamin D
supplementation on hs-CRP, and other inflammatory biomarkers
including sICAM-1, has reported no impact on hs-CRP [weighted
mean difference (WMD): −0.26 mg/L; 95% CI: −0.75, 0.22
mg/L; n = 26 arms; heterogeneity P = 0.0042; I2 = 54.2%),
sICAM-1 (WMD: −0.79 pg/mL; 95% CI: −1.33, 0.26 pg/mL;
n = 4 arms; heterogeneity P < 0.001; I2 = 62.1%), and 10 other
biomarkers with vitamin D supplementation (38). Furthermore,
the 2 studies identified to examine the impact of vitamin D
supplementation on AGP (Supplemental Table 5) have also
reported inconsistent results (39, 40). However, these results
should be interpreted with caution because the RCTs included
in the systematic review were performed on wider age groups,
had small population samples, included vitamin D–deficient
individuals at baseline, and were in populations with chronic
diseases, resulting in heterogeneity in the interpretation of the
results (38). RCTs with large sample sizes and longer follow-
























































































































































































































































































































































































































































































































































































































TABLE 3 Total effects from multivariable MR: BMI to inflammatory
markers (CRP, sICAM-1, and AGP) and 25(OH)D (Figure 1C). MR
estimates from the application of weighted median MR, IVW, and
MR–Egger methodologies1
Method Estimate SE 95% CI P value
BMI–CRP
Weighted median MR 0.390 0.025 0.342, 0.439 0.000
IVW 0.393 0.027 0.341, 0.445 0.000
MR—Egger 0.467 0.070 0.330, 0.604 0.000
(Intercept) − 0.001 0.001 − 0.004, 0.001 0.252
BMI–sICAM-1
Weighted median MR 0.330 0.106 0.122, 0.539 0.002
IVW 0.242 0.060 0.125, 0.360 0.000
MR–Egger 0.298 0.157 − 0.010, 0.605 0.058
(Intercept) − 0.001 0.003 − 0.006, 0.004 0.703
BMI–AGP
Weighted median MR 0.346 0.054 0.240, 0.452 0.000
IVW 0.281 0.033 0.216, 0.346 0.000
MR–Egger 0.342 0.087 0.171, 0.513 0.000
(Intercept) − 0.001 0.001 − 0.004, 0.002 0.449
BMI–25(OH)D
Weighted median MR − 2.126 0.277 − 2.668, −1.584 0.000
IVW − 2.516 0.209 − 2.925, −2.107 0.000
MR–Egger − 1.532 0.547 − 2.603, −0.461 0.005
(Intercept) − 0.017 0.009 − 0.035, 0.000 0.051
1AGP, α1-acid glycoprotein; CRP, C-reactive protein; IVW,
inverse-variance weighted; MR, Mendelian randomization; sICAM-1,
soluble intercellular adhesion molecule 1; 25(OH)D, 25-hydroxyvitamin D.
up periods should be considered for future investigations to
conclusively understand the role vitamin D supplementation has
on inflammatory pathways.
It has been suggested that serum 25(OH)D status could
modulate the inflammatory profile in individuals with overweight
and obesity (52). However, BMI was reported to be causally
associated with lower 25(OH)D, and vitamin D reduction in
TABLE 4 25(OH)D to inflammatory biomarkers (CRP, sICAM-1, and
AGP) (Figure 1B). MR analysis results estimates from the application of
weighted median MR, IVW, and MR–Egger methodologies1
Method Estimate2 SE 95% CI P value
25(OH)D–CRP
Weighted median MR 0.002 0.001 −0.001, 0.004 0.167
IVW − 0.001 0.003 −0.007, 0.005 0.686
MR–Egger 0.000 0.004 −0.008, 0.009 0.913
(Intercept) − 0.002 0.004 −0.009, 0.005 0.614
25(OH)D–sICAM-1
Weighted median MR − 0.003 0.005 −0.013, 0.008 0.589
IVW − 0.002 0.004 −0.009, 0.005 0.585
MR–Egger 0.000 0.006 −0.011, 0.011 0.945
(Intercept) − 0.002 0.005 −0.011, 0.007 0.691
25(OH)D–AGP
Weighted median MR 0.004 0.003 −0.002, 0.010 0.154
IVW − 0.001 0.004 −0.008, 0.006 0.748
MR–Egger 0.007 0.005 −0.004, 0.017 0.223
(Intercept) − 0.009 0.005 −0.018, 0.000 0.054
1AGP, α1-acid glycoprotein; CRP, C-reactive protein; IVW,
inverse-variance weighted; MR, Mendelian randomization; sICAM-1,
soluble intercellular adhesion molecule 1; 25(OH)D, 25-hydroxyvitamin D.
2Estimates represent the estimated casual effect of 25(OH)D on
inflammatory markers.
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TABLE 5 Direct effects from multivariable MR: BMI to inflammatory markers [25(OH)D adjusted] and 25(OH)D to inflammatory biomarkers (BMI
adjusted)1
Estimate SE 95% CI P value
Direct effects of BMI and 25(OH)D on CRP
BMI 0.385 0.028 0.330, 0.715 <2 × 10−16
25(OH)D − 0.0006 0.002 −0.005, 0.003 0.744
Direct effects of BMI and 25(OH)D on sICAM-1
BMI 0.234 0.059 0.118, 0.349 9.51 × 10−5
25(OH)D − 0.003 0.004 −0.011, 0.005 0.371
Direct effects of BMI and 25(OH)D on AGP
BMI 0.264 0.038 0.189, 0.338 9.04 × 10−12
25(OH)D − 0.002 0.002 −0.006, 0.004 0.455
1AGP, α1-acid glycoprotein; CRP, C-reactive protein; MR, Mendelian randomization; sICAM-1, soluble intercellular adhesion molecule 1; 25(OH)D,
25-hydroxyvitamin D.
relation to higher BMI might contribute to increased BMI-
related inflammation (13). In this case, vitamin D supple-
mentation might be required in obese individuals to both
replenish lowered 25(OH)D concentration and decrease the
BMI-associated metabolic health outcomes (53). RCTs with
vitamin D supplementation in adults with overweight or obesity
have reported little to no evidence on the beneficial effects
of supplementation in improving inflammation or the obesity-
related metabolic health outcomes (Supplemental Table 3) (54–
56). Our results are supported by a previous systematic review
of RCTs that examined the association between vitamin D
supplementation and inflammatory biomarkers and glycemic
outcomes of overweight and obese adults (57). In addition, a
recent systematic review and meta-analysis of completed RCTs
that examined overweight and obese individuals with vitamin
D supplementation has reported that the obese state decreased
25(OH)D concentration by −38.17 nmol/L (95% CI: −59.90,
−16.44 nmol/L) compared with the normal-weight group (58).
It is noteworthy that 55 registered trials are still ongoing,
and we recommend analyzing in greater details the impact
of vitamin D supplementation on inflammation and obesity-
related health outcomes. Furthermore, we have recently evaluated
the association of the vitamin D status in older subjects born
in 1945 from the Oulu region and found that low vitamin
D status was associated with a high prevalence of metabolic
syndrome (59). Recently, the vitamin D intervention trial in type
2 diabetes, consisting of 2423 participants supplemented with
either 4000 IU vitamin D or placebo, failed to show a significant
reduction in risk of diabetes (60). However, subgroup analyses
in the type 2 diabetic subjects demonstrated that vitamin D
supplementation had a lowering effect on the risk of diabetes
in the study population with BMI <30 compared with subjects
with BMI ≥30 (60). Therefore, in future RCTs, dosing and
confounding in different BMI classes would need more careful
considerations.
Strengths and limitations
To our knowledge this is the first study to investigate a compre-
hensive panel of inflammatory biomarkers in relation to 25(OH)D
and BMI adjusting for multiple lifestyle covariates. In addition,
this is the first study to use MR and MR mediation analyses to
test if the association between vitamin D status and inflammatory
biomarkers is likely to be causal. The 2-sample MR approach
(34) using the GWAS data sources does not require genetic
associations with BMI, 25(OH)D, and AGP/CRP/sICAM-1 to be
measured within the same population, which helps to overcome
low power issues related to the availability of gene exposure
and gene outcome data from the same study. Finally, we have
tested our hypothesis using observational data from NFBC1966,
publicly available GWAS summary statistics to examine the
causal relation between 25(OH)D and inflammatory biomarkers,
observational mediation, and MR mediation analysis to examine
the role of vitamin D as a mediator, and followed the MR
reporting checklist (61).
We acknowledge some limitations. Although BMI is an easily
accessible measure of excessive body weight in the general
population, it cannot differentiate between fat and lean body
mass. Individuals with normal weight can still demonstrate
harmful adiposity traits (62). Our study only considered BMI
as a measure of adiposity and would not be sensitive to
this. Furthermore, our findings were restricted to individuals
of European descent. Further work, including validation in
other populations, is required to replicate our findings across
ethnicities. Concurrently, our intended follow-up study from
NFBC1966 at 46 y might provide more information on validation
of these findings between vitamin D, BMI, and inflammation at
a different age group in the future.
Conclusions
The present study reports novel findings of clinical importance.
We have reported: 1) the molecular clustering of 16 inflammatory
biomarkers; 2) the complex association between BMI and
the inflammatory biomarkers, suggesting that obesity might
influence multiple inflammatory pathways differently; 3) the
consistent inverse association of vitamin D with inflammatory
biomarkers; 4) observational mediation analysis and 2-sample
MR and MR mediation analysis to ascertain the causality
between serum 25(OH)D and inflammatory biomarkers does
not support the role of vitamin D as a causal mediator of
BMI-associated inflammation although we show BMI’s causal
role on 3 tested inflammatory markers as a part of mediation
analyses; and 5) further interpretation supported by the review
of vitamin D supplementation RCTs also reported inconsistent
results. Overall, this study does not support the hypothesis that
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low vitamin D status co-occurring with obesity contributes to
aggravation of the inflammatory status.
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